Home > Insider Trading > Filing (0000899243-19-026599)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1720725	Oyster Point Pharma Inc.	OYST	Biological Products, (No Disgnostic Substances) (2836)	811030955

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1746742	Clare Ozawa	C/O Oyster Point Pharma, Inc. 202 Carnegie Center, Suite 109 Princeton NJ 08540		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $0.001 Per Share	Acquisiton	2019-11-04	1,941,500	$0.00	1,941,500	No	4	C	Indirect	See footnotes
Common Stock, Par Value $0.001 Per Share	Acquisiton	2019-11-04	495,388	$0.00	2,436,888	No	4	C	Indirect	See footnotes
Common Stock, Par Value $0.001 Per Share	Acquisiton	2019-11-04	125,000	$16.00	2,561,888	No	4	P	Indirect	See footnotes
Common Stock, Par Value $0.001 Per Share	Acquisiton	2019-11-04	566,158	$0.00	566,158	No	4	C	Indirect	See footnotes
Common Stock, Par Value $0.001 Per Share	Acquisiton	2019-11-04	437,500	$16.00	1,003,658	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	P	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	P	Indirect	See footnotes

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock, Par Value $0.001 Per Share	Series A Convertible Preferred Stock	Disposition	2019-11-04	1,941,500	$0.00	1,941,500	$0.00
Common Stock, Par Value $0.001 Per Share	Series B Convertible Preferred Stock	Disposition	2019-11-04	495,388	$0.00	495,388	$0.00
Common Stock, Par Value $0.001 Per Share	Series B Convertible Preferred Stock	Disposition	2019-11-04	566,158	$0.00	566,158	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.
Shares held by Versant Vantage I, L.P. and may be deemed beneficially owned by the Reporting Person by reason of the Reporting Person being a managing member of Versant Vantage I GP-GP, LLC, the general partner of Versant Vantage I GP, L.P., the general partner of Versant Vantage I, L.P.
Shares held by Versant Venture Capital VI, L.P. ("Versant VI") and may be deemed beneficially owned by the Reporting Person as of November 1, 2019 upon becoming a managing member of Versant Ventures VI GP-GP, LLC, the general partner of Versant Ventures VI GP, L.P., the general partner of Versant VI.
The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.